Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

11.89
+0.18001.54%
Post-market: 11.900.0100+0.08%19:54 EDT
Volume:2.03M
Turnover:24.18M
Market Cap:1.06B
PE:-3.53
High:12.25
Open:11.78
Low:11.67
Close:11.71
52wk High:12.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:0.71
T/O Rate:2.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:21.79
PE(LYR):-3.74

Loading ...

Wedbush Sticks to Its Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Jun 04

Kura Oncology releases ASCO 2026 darlifarnib clinical update presentation

Reuters
·
Jun 04

Kura Oncology Plans Wider Platform Study for Darlifarnib Amid Recent Data on Anti-Tumor Activity

MT Newswires Live
·
Jun 03

Kura Oncology plans Phase 1a platform study pairing darlifarnib with daraxonrasib in KRAS-mutant pancreatic cancer

Reuters
·
Jun 03

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

GlobeNewswire
·
Jun 03

Kura Oncology says Blood paper shows 87% response rate for ziftomenib plus venetoclax/azacitidine in relapsed NPM1-mutated AML

Reuters
·
Jun 02

H.C. Wainwright Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacific Edge Limited (OtherPFGTF), Kura Oncology (KURA) and Eli Lilly & Co (LLY)

TIPRANKS
·
May 27

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), Kura Oncology (KURA) and 3SBio (OtherTRSBF)

TIPRANKS
·
May 26

Kura Oncology Reports Tumor Shrinkage in 77% of Patients in KRAS Cancer Drug Combo Trial

MT Newswires Live
·
May 26

Kura Oncology reports 67% response rate in Phase 1 darlifarnib-adagrasib trial for KRAS G12C pancreatic cancer

Reuters
·
May 26

Kura Oncology Reports Strong Clinical Activity and Safety With Darlifarnib + Adagrasib in Kras G12c-Mutated Solid Tumors

THOMSON REUTERS
·
May 26

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

GlobeNewswire
·
May 26

Kura Oncology Chief Commercial Officer Brian Powl sells 10,000 shares for $110,000

Reuters
·
May 23

Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
May 21

Kura Oncology CCO Brian Powl sells 339 shares worth $3,122.19

Reuters
·
May 21

Kura Oncology Chief Legal Officer Teresa Bair disposes 2,256 shares worth $21,159.19

Reuters
·
May 21

Kura Oncology COO Kathleen Ford sells 2,257 shares for $20,484.71

Reuters
·
May 21

Kura Oncology Earnings Call Signals Early Launch Strength

TIPRANKS
·
May 20

Kura Oncology joins TD Cowen Oncology Innovation Summit fireside chat

Reuters
·
May 20